Stoke Therapeutics, Inc.
STOK Nasdaq
SEC CIK 1623526
Follow Stoke Therapeutics
Weekly email: filings, results
Revenue, last quarter
$11.3M
+5.9% vs same quarter last year
Net income
−$73.6M
−92% vs same quarter last year
EPS, diluted
−$1.08
−66.2% vs same quarter last year
Operating cash flow
−$62.7M
−106.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $184.4M | −$6.9M |
| FY24 | $36.6M | −$89M |
| FY23 | $8.8M | −$104.7M |
| FY22 | $12.4M | −$101.1M |
| FY21 | - | −$85.8M |
| FY20 | - | −$52.2M |
| FY19 | - | −$32.3M |
| FY18 | - | −$12.5M |
| FY17 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −11.2% | −3.7% |
| FY24 | −277.3% | −243.4% |
| FY23 | −1307.2% | −1192.5% |
| FY22 | −841.2% | −814.7% |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $44.9M |
| FY24 | −$87.1M |
| FY23 | −$82.7M |
| FY22 | −$35.8M |
| FY21 | −$68.1M |
| FY20 | −$43.3M |
| FY19 | −$32.7M |
| FY18 | −$11.9M |
| FY17 | - |
- Stoke Therapeutics
- Healthcare median
Show the numbers
| Year | Stoke Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −3.7% | −30.6% |
| FY24 | −243.4% | −47% |
| FY23 | −1192.5% | −58% |
| FY22 | −814.7% | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |